
Lebrikizumab sustains atopic dermatitis clearance up to 2 years with less frequent dosing, per new long-term data.
New long-term data from the ADjoin trial shows that lebrikizumab, an injectable treatment for moderate to severe atopic dermatitis, maintains skin clearance and reduces itching for up to 2 years even with monthly dosing instead of biweekly. About 76%...
